OptiFlex Complete and Rosuvastatin Calcium

• Generic Name: chondroitin / glucosamine
• Dosage Forms: n.a.
• Other Brand Names: Artificial Tears, Celluvisc, Clear Eyes CLR, GenTeal, Hypotears, Isopto Tears, Lacri-Lube SOP, Liquitears, Moisture Drops, Oasis Tears, Opti-Free Rewetting Drops, Optive, Refresh, Soothe, Systane, TheraTears, Ultra Fresh, Visine Tears, Chondroitin-Glucosamine, Schiff Move Free Caplets, Osteo Bi-Flex Double Strength, Osteo Bi-Flex Triple Strength, Osteo Bi-Flex Edge Joint & Energy, OptiFlex Sport

Chondroitin is a naturally occurring substance formed of sugar chains. Chondroitin is believed to help the body maintain fluid and flexibility in the joints.

Glucosamine is sugar protein that helps your body build cartilage (the hard connective tissue located mainly on the bones near your joints). Glucosamine is a naturally occurring substance found in bones, bone marrow, shellfish and fungus.

OptiFlex Complete is a combination product that has been used in alternative medicine as a possibly effective aid in treating osteoarthritis pain.

Other uses not proven with research have included treating rheumatoid arthritis, osteoporosis, cataracts, glaucoma, bladder problems, heart disease, high cholesterol, or TMJ (temporomandibular joint disease).

It is not certain whether OptiFlex Complete is effective in treating any medical condition. Medicinal use of this product has not been approved by the FDA. This medicine should not be used in place of medication prescribed for you by your doctor.

OptiFlex Complete is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.

OptiFlex Complete may also be used for purposes not listed in this product guide.

• Generic Name: rosuvastatin
• Dosage Forms: n.a.
• Other Brand Names: Crestor, Ezallor Sprinkle

ACC/AHA cholesterol management guideline recommends statins as first-line therapy for prevention of atherosclerotic cardiovascular disease (ASCVD) in adults; extensive evidence demonstrates that statins can substantially reduce ASCVD risk when used for secondary prevention or primary prevention (in high-risk patients). Relative reduction in ASCVD risk is correlated with degree of LDL-cholesterol lowering; therefore, use maximum tolerated statin intensity to achieve optimum ASCVD benefits. According to ACC/AHA, rosuvastatin may be used for primary or secondary prevention in adults when moderate- or high-intensity statin therapy is indicated. (See Prevention of Cardiovascular Events under Dosage and Administration.)

Adjunct to nondrug therapies (i.e., lifestyle modifications) in patients without clinical evidence of CHD who have multiple risk factors (e.g., age, smoking, hypertension, low HDL-cholesterol concentrations, family history of early CHD) to reduce the risk of MI, stroke, or angina and the risk of undergoing revascularization procedures. Consider benefits, adverse effects, drug interactions, and patient preferences before initiating statin therapy for primary prevention.

Adjunct to dietary therapy to slow the progression of atherosclerosis as part of a treatment strategy to lower total and LDL-cholesterol concentrations to target levels.

Dyslipidemias

Adjunct to nondrug therapies (e.g., dietary management) in adults to decrease elevated serum total cholesterol, LDL-cholesterol, apolipoprotein B (apo B), non-HDL-cholesterol, and triglyceride concentrations, and to increase HDL-cholesterol concentrations in the management of primary hyperlipidemia or mixed dyslipidemia. Also used in combination with fenofibrate to decrease triglyceride concentrations and increase HDL-cholesterol concentrations in patients with mixed dyslipidemia and CHD (or CHD risk equivalents) who are on optimal statin therapy; however, no incremental benefit on cardiovascular morbidity and mortality beyond that provided by statin monotherapy.

Adjunct to nondrug therapies (e.g., dietary management) to decrease elevated serum total cholesterol, LDL-cholesterol, and apo B concentrations in the management of heterozygous familial hypercholesterolemia in children and adolescents 8–17 years of age who, despite an adequate trial of dietary management, have a serum LDL-cholesterol concentration >190 mg/dL or a serum LDL-cholesterol concentration >160 mg/dL and either a family history of premature cardiovascular disease or ≥2 other cardiovascular risk factors.

Reduction of elevated serum total cholesterol, LDL-cholesterol, and apo B concentrations in adults with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies (e.g., plasma LDL-apheresis) or when such therapies are not available.

Adjunct to nondrug therapies (e.g., dietary management) to decrease elevated serum LDL-cholesterol, total cholesterol, non-HDL-cholesterol, and apo B concentrations in children and adolescents 7–17 years of age with homozygous familial hypercholesterolemia; used alone or in conjunction with other lipid-lowering therapies (e.g., LDL apheresis).

Adjunct to nondrug therapies (e.g., dietary management) for the management of hypertriglyceridemia. However, fibric acid derivatives provide greater benefit in patients with elevated triglyceride concentrations compared with statins.

Adjunct to nondrug therapies (e.g., dietary management) for the management of primary dysbetalipoproteinemia (Fredrickson type III).

Produces greater reductions in LDL-cholesterol concentrations than atorvastatin, pravastatin, or simvastatin on a mg-for-mg basis.